Key result
Baseline obstructive CAD in TAVI patients is linked to ~74% higher 30-day mortality.
Why the study?
Does obstructive CAD and its management with PCI prior to TAVI impact short-term mortality in patients undergoing TAVI?
Cohort (n=896)
Yes
Does obstructive CAD and its management with PCI prior to TAVI impact short-term mortality in patients undergoing TAVI?
Hazard Ratio: 1.74 (95% CI 1.03–2.94)
Absolute Event Rate: 8.7% vs 5.1%
p-value: p=0.037
Obstructive CAD negatively impacts short-term survival after TAVI, but revascularization with PCI prior to TAVI appears to mitigate this risk, yielding survival comparable to patients without CAD.
Obstructive CAD may raise post-TAVI mortality; pre-TAVI PCI appears mitigating but requires RCTs before practice change.
BACKGROUND: Coronary artery disease (CAD) and degenerative aortic stenosis often coexist. However, the impact of CAD and its management on the prognosis after transcatheter aortic valve implantation (TAVI) remains uncertain. We sought to evaluate the impact of obstructive CAD, SYNTAX score (Ss), and percutaneous coronary intervention (PCI) prior to TAVI on short-term outcome. METHODS: Overall, 896 patients who underwent TAVI after heart team decision was included. Pre-procedural angiograms were analysed to calculate baseline Ss (bSs) and residual Ss (rSs). Baseline, procedural and follow-up data up to 30 days was acquired from the national POL-TAVI registry. RESULTS: Patients with obstructive CAD at baseline (n = 462, 52%) had higher mortality as compared with the remaining (8.7 vs. 5.1%, log-rank P = 0.039). Also, after correction for confounding factors obstructive CAD was identified as independent predictor of mortality (hazard ratio [HR] 1.74, 95% confidence intervals [CIs] 1.03-2.94, P = 0.037). In obstructive CAD, neither bSs (AUC 0.47, CI 0.38-0.56, P = 0.47) nor rSs (AUC 0.47, CI 0.30-0.64, P = 0.72 for those undergoing PCI and AUC 0.48, CI 0.37-0.59, P = 0.75 for the remaining) was predictive of mortality. When revascularization status was considered, patients with PCI prior to TAVI had similar outcome as those without obstructive CAD at baseline (7.7 vs. 5.1%, log-rank P = 0.23) with no negative impact on mortality (HR 1.13, CI 0.62-2.09, P = 0.69). CONCLUSIONS: In conclusion, obstructive CAD at baseline evaluation for TAVI has independent negative impact on short-term prognosis. However, neither baseline nor residual Ss values have prognostic ability in patients undergoing TAVI. Revascularization prior to TAVI seems to improve survival to levels comparable with patients without obstructive CAD at baseline.
No takes yet. Share an insight, caveat, or question.
Huczek et al. (2017) conducted a cohort in Transcatheter aortic valve implantation (TAVI) with or without coronary artery disease (n=896). Obstructive coronary artery disease vs. No obstructive coronary artery disease was evaluated on Mortality up to 30 days (HR 1.74, 95% CI 1.03-2.94, p=0.037). Obstructive coronary artery disease at baseline in patients undergoing TAVI was associated with increased 30-day mortality (8.7% vs 5.1%; HR 1.74; 95% CI 1.03-2.94; P=0.037).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: